Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Anchorage Radiation Therapy Center — Anchorage, Alaska
+ 1223 more sites in the U.S.
Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Anchorage Radiation Therapy Center — Anchorage, Alaska
+ 952 more sites in the U.S.
Phase 3 Recruiting NIH
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 nega…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06058377
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Katmai Oncology Group — Anchorage, Alaska
- University of Arizona Cancer Center-Orange Grove Campus — Tucson, Arizona
+ 555 more sites in the U.S.
Phase 3 Recruiting NIH
This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer ret…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07391774
Locations: - NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
- Sutter Auburn Faith Hospital — Auburn, California
- Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
+ 198 more sites in the U.S.
Phase 3 Recruiting Industry
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…
Sponsor: Gilead Sciences
NCT ID: NCT05633654
Locations: - Alabama Oncology — Birmingham, Alabama
- Clearview Cancer Institute — Huntsville, Alabama
- Palo Verde Hematology Oncology — Glendale, Arizona
+ 184 more sites in the U.S.
Phase 3 Recruiting Industry
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed def…
Sponsor: AstraZeneca
NCT ID: NCT05774951
Locations: - Research Site — Birmingham, Alabama
- Research Site — Dothan, Alabama
- Research Site — Anchorage, Alaska
+ 124 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positi…
Sponsor: Pfizer
NCT ID: NCT07062965
Locations: - Ironwood Cancer & Research Centers — Chandler, Arizona
- Ironwood Cancer & Research Centers — Gilbert, Arizona
- Ironwood Cancer & Research Centers — Glendale, Arizona
+ 99 more sites in the U.S.
Phase 3 Recruiting Academic/Other
The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 60 years) tolerate side effects and stay on treatment longer, to der…
Sponsor: American Society of Clinical Oncology
NCT ID: NCT06377852
Locations: - Ironwood Cancer & Research Centers — Chandler, Arizona
- Ironwood Cancer & Research Centers — Gilbert, Arizona
- Ironwood Cancer & Research Centers — Glendale, Arizona
+ 85 more sites in the U.S.
Phase 3 Recruiting Industry
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metasta…
Sponsor: BriaCell Therapeutics Corporation
NCT ID: NCT06072612
Locations: - Mayo Clinic-Comprehensive Cancer Center-Breast Clinic — Phoenix, Arizona
- University of Arizona-Cancer Center — Tucson, Arizona
- Los Angeles cancer Network_Anaheim — Anaheim, California
+ 76 more sites in the U.S.
Phase 3 Recruiting Industry
This is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatment group. This trial will be double-blinded, which means neither the participant…
Sponsor: BioNTech SE
NCT ID: NCT07173751
Locations: - Highlands Oncology Group — Springdale, Arkansas
- University Of California - San Diego Moores Cancer Center — La Jolla, California
- Cancer and Blood Specialty Clinic (CBSC) — Los Alamitos, California
+ 68 more sites in the U.S.
Phase 3 Recruiting Industry
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…
Sponsor: AstraZeneca
NCT ID: NCT06103864
Locations: - Research Site — Daphne, Alabama
- Research Site — Springdale, Arkansas
- Research Site — Duarte, California
+ 64 more sites in the U.S.
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in th…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06966700
Locations: - Banner MD Anderson Cancer Center ( Site 0066) — Gilbert, Arizona
- Mayo Clinic Cancer Center ( Site 0034) — Phoenix, Arizona
- University of Arizona Cancer Center ( Site 0035) — Tucson, Arizona
+ 60 more sites in the U.S.